Quest Diagnostics Inc (DGX) reported quarterly earnings results on Thursday, Apr-21-2016. The company reported $1.12 EPS for the quarter. Analysts had a consensus estimate of $1.12. The company posted revenue of $1863.00 million in the period, compared to analysts expectations of $1823.36 million. The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.05 EPS.
Many Wall Street Analysts have commented on Quest Diagnostics Inc. Quest Diagnostics Inc was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Sector Perform” and Lowered the Price Target to $ 70 from a previous price target of $73 .
Quest Diagnostics Inc opened for trading at $74.4 and hit $75.07 on the upside on Monday, eventually ending the session at $74.75, with a gain of 0.40% or 0.3 points. The heightened volatility saw the trading volume jump to 8,09,425 shares. Company has a market cap of $10,671 M.
In a different news, on Mar 3, 2016, Michael E Prevoznik (SVP & General Counsel) sold 3,815 shares at $68.40 per share price. According to the SEC, on Aug 13, 2015, John C Md Baldwin (director) sold 2,266 shares at $72.00 per share price. On Aug 10, 2015, John B Ziegler (director) sold 2,200 shares at $74.35 per share price, according to the Form-4 filing with the securities and exchange commission.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.